Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FDJD0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,642
Award facts
- Contract value 100% obligated
- $14,642.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $14,642.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. DMS Pharmaceutical Group is a critical supplier within the federal pharmaceutical supply chain specializing in distributing branded and generic prescription medications, biologics, vaccines, and medical consumables to Department of Defense healthcare facilities. The contract carries a firm fixed-price structure with no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. The award was made on November 13, 2025, with an ultimate completion date of November 14, 2025.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying indefinite delivery contract, valued at $499.999 billion, was awarded to DMS Pharmaceutical Group on November 13, 2025, and authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide through December 31, 2036. The contract structure includes a 30-month base period with three additional 30-month option periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DR26FDJD0?
SPE2DR26FDJD0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FDJD0 worth?
The government has obligated $14,642 on SPE2DR26FDJD0.
Is contract SPE2DR26FDJD0 an order under another contract?
Yes. SPE2DR26FDJD0 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJD0 competed?
The extent of competition for SPE2DR26FDJD0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award